Needham & Company LLC reaffirmed their hold rating on shares of Amphastar Pharmaceuticals (NASDAQ:AMPH – Free Report) in a report released on Wednesday morning, Benzinga reports. A number of other equities research analysts also recently weighed in on AMPH. JPMorgan Chase & Co. began coverage on shares of Amphastar Pharmaceuticals in a research note on […]
StockNews.com started coverage on shares of Pieris Pharmaceuticals (NASDAQ:PIRS – Free Report) in a research note issued to investors on Thursday morning. The brokerage issued a hold rating on the biotechnology company’s stock. Pieris Pharmaceuticals Stock Down 0.1 % NASDAQ PIRS opened at $10.48 on Thursday. The business’s 50-day moving average price is $12.87 and […]
Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) had its target price boosted by Robert W. Baird from $52.00 to $62.00 in a research report sent to investors on Thursday morning, Benzinga reports. The brokerage currently has an outperform rating on the stock. Several other equities research analysts also recently weighed in on CRNX. Morgan Stanley upped […]
Westfield Capital Management Co. LP acquired a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 237,495 shares of the biopharmaceutical company’s stock, valued at approximately $10,939,000. Westfield Capital Management Co. […]
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) – Equities researchers at Zacks Research increased their Q2 2024 earnings per share (EPS) estimates for shares of Agios Pharmaceuticals in a research note issued to investors on Monday, May 20th. Zacks Research analyst A. Chakraborty now anticipates that the biopharmaceutical company will earn ($1.59) per share for […]